- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00634088
Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
February 9, 2016 updated by: R-Pharm
Parallel Phase I Study of Ixabepilone Plus Lapatinib and Ixabepilone Plus Lapatinib Plus Capecitabine in Subjects With HER2 Positive Locally Advanced or Metastatic Breast Cancer
The purpose of this study is to determine the safety and preliminary effectiveness of ixabepilone plus lapatinib with and without capecitabine in the treatment of human epidermal growth factor receptor 2 (HER2)-positive or metastatic breast cancer.
Study Overview
Status
Terminated
Conditions
Study Type
Interventional
Enrollment (Actual)
13
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Queensland
-
Brisbane, Queensland, Australia, 4101
- Local Institution
-
-
-
-
-
Modena, Italy, 41100
- Local Institution
-
-
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08901
- The Cancer Institute of New Jersey
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Females aged 18 years or older with histologic or cytologic diagnosis of adenocarcinoma originating in the breast
- Radiologic or pathologic evidence that the cancer is metastatic or locally advanced (a T4 tumor and stage IIIB/IIIC disease) and not curable by local measures, such as radiation or surgery
- Positive status for human epidermal growth factor receptor 2
- Measurable disease as per Response Evaluation Criteria In Solid Tumors guidelines
- Karnofsky performance status of 70 to 100
- Life expectancy of at least 3 months
Exclusion Criteria:
- Prior radiation must not have included 30% or more of major bone-marrow containing areas, such as the pelvis and lumbar spine
- Common Terminology Criteria Grade 2 or greater neuropathy
- Inadequate hematologic, hepatic, or renal function
- Known prior severe hypersensitivity reactions to agents containing Cremophor® EL or known hypersensitivity or prior intolerance to fluoropyrimidine
- Known or suspected dihydropyrimidine dehydrogenase deficiency
- More than 3 prior chemotherapy regimens in the metastatic setting
- Prior treatment with an epothilone or lapatinib; prior treatment with capecitabine within the past 6 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg
Dose Level 1
|
Lapatinib, 1000 mg, administered orally, once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone (Day 1).
Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m^2, administered as a 3-hour IV infusion.
Lapatinib, 1000 mg, administered orally, once a day, every day, for a 21-day cycle.
|
Experimental: Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg
Dose Level 2
|
Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m^2 + lapatinib, 1000 mg).
Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone.
Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m^2, administered as a 3-hour IV infusion.
Lapatinib administered, 1250 mg, orally, once a day, every day, for a 21-day cycle.
|
Experimental: Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg
Dose Level 3
|
Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m^2 + lapatinib, 1250 mg).
Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone.
Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 40 mg/m^2, administered as a 3-hour IV infusion.
Lapatinib, 1250 mg, administered orally, once a day, every day, for a 21-day cycle.
|
Experimental: Ixabepilone + Lapatinib + Capecitabine
Triplet Combination
|
Planned escalating doses of the triplet combination of ixabepilone, lapatinib, and capecitabine.
No participants were enrolled in this arm due to premature termination of the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D) of Ixabepilone When Administered With Lapatinib
Time Frame: Days 1 through 21
|
The MTD is defined as the maximum dose that can be administered to 6 participants such that no more than 1 (or fewer than one third if more than 6 participants receive treatment) experiences a dose-limiting toxicity (DLT), with at least 2 experiencing a DLT at the next higher dose level.
The RP2D is based on the MTD and the assessment of any relevant chronic toxicities.
|
Days 1 through 21
|
MTD and RP2D of Ixabepilone When Administered With Lapatinib Plus Capecitabine
Time Frame: Days 1 through 21
|
MTD is defined as the maximum dose that can be administered to 6 participants such that no more than 1 (or fewer than one third if more than 6 participants receive treatment) experiences a DLT, with at least 2 experiencing a DLT at the next higher dose level.
The RP2D is based on the MTD and the assessment of any relevant chronic toxicities.
|
Days 1 through 21
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, Treatment-related AEs, Treatment-related AEs (Grade 3 or 4), Peripheral Neuropathy (PN), PN (Grade 3 or 4)
Time Frame: Baseline to Day 21, continuously
|
AE=Any new untoward medical event or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment.
SAE=any untoward medical event that results in death, persistent or significant disability/incapacity, drug dependency or abuse; is life-threatening, important, a congenital anomaly/birth defect; or requires or prolongs existing hospitalization.
Treatment related=possibly, probably, or certainly related to and of unknown relationship to study treatment.
Common Terminology Criteria (CTC) Grade 3=severe; Grade 4=life-threatening or disabling.
|
Baseline to Day 21, continuously
|
Number of Participants With DLT
Time Frame: Baseline to Day 21, continuously
|
DLT=Any of the following events, attributable to study drug and occurring within 21 days after ixabepilone administration: Grade 3 or 4 nausea, vomiting, or diarrhea despite the use of adequate medical intervention; other Grade 3 or greater nonhematologic toxicity requiring removal from study drug; recovery from study drug-related toxicity that delayed scheduled retreatment for longer than 3 weeks; Grade 4 neutropenia for 5 or more consecutive days or Grade 3 or 4 neutropenia of any duration with sepsis or fever; thrombocytopenia or bleeding requiring platelet transfusion.
|
Baseline to Day 21, continuously
|
Number of Participants With Abnormalities in Hematology Laboratory Results by Worst CTC Grade
Time Frame: Baseline and weekly from Days 1 to 21 (Cycle 1)
|
CTC, Version 3.0 used to assess parameters.
ULN=upper level of normal among all laboratory ranges.
WBC (c/L): Grade (Gr)1:<LLN to 3.0*10^9/L, Gr 2:<3.0 to 2.0*10^9/L, Gr 3:<2.0 to 1.0*10^9/L, Gr 4:<1.0*10^9/L;
ANC (c/uL): Gr 1:<LLN to 1.5*10^9/L, Gr 2:<1.5 to 1.0*10^9/L, Gr 3:<1.0 to 0.5*10^9/L, Gr 4:<0.5*10^9/L;
Platelet count (c/uL): Gr 1:LLN to 75.0*10^9/L, Gr 2:<75.0 to 50.0*10^9/L, Gr 3:<50.0 to 25.0*10^9/L, Gr 4:<25.0*10^9/L;
Hemoglobin (g/dL): Gr 1:<LLN to 10.0 g/dL, Gr 2:<10.0 to 8.0 g/dL, Gr 3:<8.0 to 6.5 g/dL, Gr 4:<6.5 g/dL.
|
Baseline and weekly from Days 1 to 21 (Cycle 1)
|
Number of Participants With Abnormalities in Serum Chemistry Laboratory Results by Worst CTC Grade
Time Frame: At baseline and within 72 hours of Day 1 of 21-day cycle
|
CTC, Version 3.0 used to assess parameters.
ULN=upper level of normal among all laboratory ranges.
ALT(U/L) Gr 1:>ULN-2.5*ULN,Gr
2:>2.5-5.0*ULN,Gr
3:>5.0-20.0*ULN,Gr
4:>20.0*
ULN; AST(U/L) Gr 1:>ULN-2.5*
ULN,Gr 2:>2.5-5.0*ULN,Gr
3:>5.0-20.0*ULN,Gr
4:>20.0*
ULN; ALP(U/L)Gr 1:>ULN-2.5*ULN,
Gr 2:>2.5-5.0*ULN,
Gr 3:>5.0-20.0*ULN,
Gr 4:>20.0*ULN;
Creatinine (mg/dL): Gr 1:>ULN-1.5*ULN,
Gr 2:>1.5-3.0*ULN,
Gr 3:>3.0-6.0*ULN,
Gr 4:>6.0*ULN;
Total bilirubin (mg/dL): Gr 1:>ULN-1.5*ULN,
Gr 2:>1.5-3.0*ULN,
Gr 3:>3.0-10.0*ULN,
Gr 4:>10.0*ULN
|
At baseline and within 72 hours of Day 1 of 21-day cycle
|
Maximum Concentration of Ixabepilone
Time Frame: Day 1 of 21-day cycle
|
Day 1 of 21-day cycle
|
|
Area Under the Concentration-time Curve From 0 to Infinity (AUC[INF]) and AUC From 0 to Last Quantifiable Concentration (AUC[O-T] of Ixabepilone
Time Frame: Day 1 of 21-day cycle
|
Day 1 of 21-day cycle
|
|
Terminal Half-life of Ixabepilone
Time Frame: Day 1 of 21-day cycle
|
Day 1 of 21-day cycle
|
|
Time to Peak Concentration of Ixabepilone
Time Frame: Day 1 of 21-day cycle
|
Day 1 of 21-day cycle
|
|
Volume of Distribution at Steady State of Ixabepilone
Time Frame: Day 1 of 21-day cycle
|
Day 1 of 21-day cycle
|
|
Overall Tumor Response By Number of Participants
Time Frame: Baseline and Day 21 (21-day cycle)
|
Target lesion criteria: Complete Response(CR)=Disappearance of all clinical and radiologic evidence of target lesions; Partial Response (PR)=A 30% or greater decrease in the sum of longest diameter(LD) of all lesions in reference to the baseline sum LD.
Stable Disease (SD)=Insufficient increase to qualify for Progressive Disease (PD) and insufficient shrinkage to qualify for PR; PD=A 20% or greater increase in the sum of LD of all target lesions, taking as reference the smallest sum LD recorded at or following baseline.
|
Baseline and Day 21 (21-day cycle)
|
Duration of Response of Combination Treatment With Ixabepilone Plus Lapatinib
Time Frame: First occurrence of PR or CR to PD or Death (no average, as no data available)
|
Duration of response is measured from the time in months that measurement criteria are first met for PR or CR, whichever is recorded first, until the date of documented PD or death.
Participants who neither relapse nor die will be censored on the date of their last tumor assessment.
|
First occurrence of PR or CR to PD or Death (no average, as no data available)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2008
Primary Completion (Actual)
June 1, 2010
Study Completion (Actual)
June 1, 2010
Study Registration Dates
First Submitted
March 5, 2008
First Submitted That Met QC Criteria
March 11, 2008
First Posted (Estimate)
March 12, 2008
Study Record Updates
Last Update Posted (Estimate)
March 10, 2016
Last Update Submitted That Met QC Criteria
February 9, 2016
Last Verified
February 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Protein Kinase Inhibitors
- Capecitabine
- Lapatinib
- Epothilones
Other Study ID Numbers
- CA163-144
- EURDRACT: 2007-004123-38
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced or Metastatic Breast Cancer
-
Merck Sharp & Dohme LLCCompletedMetastatic or Locally Advanced Cancer
-
Gilead SciencesEverest MedicinesActive, not recruitingLocally Advanced or Metastatic Unresectable Urothelial CancerUnited States, Belgium, France, Spain, United Kingdom, Korea, Republic of, Czechia, Germany, Israel, China, Italy, Australia, Hong Kong, Taiwan, Portugal, Singapore, Croatia, Greece, Turkey, Sweden, Switzerland, Canada, Austria, Bulgaria and more
-
Shanghai Pharmaceuticals Holding Co., LtdRecruitingLocally Advanced or Metastatic Breast CancerChina
-
Fudan UniversityNot yet recruitingBreast Neoplasms | Locally Advanced or Metastatic Breast Cancer
-
Sun Yat-sen UniversityChengdu Biostar PharmaceuticalsNot yet recruitingBreast Neoplasms | Locally Advanced or Metastatic Breast CancerChina
-
Genor Biopharma Co., Ltd.RecruitingLocally Advanced or Metastatic Breast CancerChina
-
Eisai Korea Inc.CompletedLocally Advanced or Metastatic Breast CancerKorea, Republic of
-
Shanghai Pharmaceuticals Holding Co., LtdRecruitingLocally Advanced or Metastatic Breast CancerChina
-
Hoffmann-La RocheRecruitingLocally Advanced or Metastatic Breast CancerFrance, Belgium, United States, Korea, Republic of, Taiwan, Brazil, China, Italy, Argentina, Jordan, Mexico, Germany, Portugal, Spain, Thailand, Turkey, United Kingdom, Kenya, Hungary, Poland, Colombia, India, Oman, Uganda, United Arab... and more
-
Sermonix Pharmaceuticals Inc.Linical Accelovance GroupActive, not recruitingLocally Advanced or Metastatic Breast CancerUnited States, Canada, Israel
Clinical Trials on Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg
-
R-PharmTerminated
-
R-PharmCompletedNon-small Cell Lung Cancer (NSCLC)Japan
-
CicloMed LLCCmed Clinical ServicesCompletedAdvanced Solid TumorsUnited States
-
GlaxoSmithKlineCompletedNeoplasms, BreastUnited Kingdom, United States, Peru, Israel, Poland, Russian Federation, Korea, Republic of, Thailand, Pakistan, Hungary, India, Canada, France, Mexico, Malaysia, Singapore
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedAdvanced Solid TumorUnited States
-
R-PharmCompletedAdvanced/Metastatic Non-Small Cell Lung CancerGermany, Korea, Republic of, Russian Federation, Taiwan, Australia, Italy, France, United States, Argentina, Spain
-
R-PharmCompletedMetastatic Breast CancerItaly, United Kingdom, United States, France, Spain
-
HighField Biopharmaceuticals CorporationRecruiting
-
SunovionCompletedPediatric Attention Deficit Hyperactivity DisorderUnited States
-
Millennium Pharmaceuticals, Inc.CompletedMyelodysplastic Syndromes | Leukemia, Myeloid, AcuteJapan, Taiwan, Korea, Republic of